06990 科倫博泰生物－Ｂ
SKB BIO-B
SKB BIO-B
| Listing Date | 2023/07/11 |
| Listing Price | 60.600 |
Subscription Result
- Subscription Rate1.27x
- Guarantee One Lot Size2 lot
- One Lot Success Rate75.03%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sichuan Kelun-Biotech Biopharmaceutical Co. is a biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in oncology, immunology and other therapeutic areas in China and globally.
--
As of 20 Jun 2023, the Group strategically advance a differentiated and clinically valuable pipeline of 33 assets, including 14 in clinical stage, five in pivotal trial- or NDA registration-stage, nine in phase 1- or phase 2-stage, and nine out-license agreements.
--
The Group has two ADC drugs as its Core Products, namely, SKB264 and A166. SKB264 is a novel phase 3-stage TROP2 ADC positioned as a late-line monotherapy and part of early-line combination therapies for treating various advanced solid tumors, including breast cancer (BC), non-small cell lung cancer (NSCLC) and other major cancers. A166 is a differentiated NDA registration-stage HER2 ADC positioned as a late-line monotherapy to treat advanced HER2 solid tumors.
--
The Group also owned 79 issued patents in China, 22 issued patents in the U.S., 52 issued patents in other jurisdictions, and 255 pending patent applications.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 22.45M H shares |
| No. of International Offer Shares | 20.20M H shares |
| No. of HK Offer Shares | 2.24M H shares |
| Offer Price | $60.60 - $72.80 |
| Stock Code | 6990 |
| Sponsor(s) | Goldman Sachs (Asia) L.L.C., CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | Goldman Sachs (Asia) L.L.C., CLSA Limited, Citigroup Global Markets Asia Limited, ICBC International Securities Limited, BOCOM International Securities Limited |
TIME TABLE
| Application Period | Jun 29 (Thu) - noon, Jul 04 (Tue) |
| Price Determination Date | Jul 04 (Tue) |
| Result Announcement Date | On or before Jul 10 (Mon) |
| Result Announcement Date | On or before Jul 10 (Mon) |
| Result Announcement Date | On or before Jul 10 (Mon) |
| Dealings in Shares commence on | Jul 11, 2023. (Tue) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $60.60 - $72.80 |
| Capitalization | 13.08B - 15.71B |
| NAV / share ($) | $-11.82 - $-9.93 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 66.70, the net proceeds raised would be HKD 1.38B, of which |
| 45% : Research, development and commercialization of Core Products, namely, SKB264 and A166 |
| 30% : Research, development and commercialization of other key products, including A140, A167, A400 and A223 |
| 12% : Fund the continued development of technology platforms for ADCs, biologics and small molecules |
| 8% : Expansion of manufacturing capabilities and quality control system |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).